Breast cancer and heart disease may have common roots

December 20, 2011

Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found.

The majority of women with hereditary breast and ovarian cancer have a mutated form of the BRCA1 or BRCA2 genes, which normally suppress the growth of breast and ovarian tumours.

Dr. Subodh Verma, a cardiac surgeon at St. Michael's Hospital, said his research team was surprised to discover the genes also regulate .

Following a heart attack, mice with the mutated had a three-to-five times higher rate of death. This was largely due to the development of profound heart failure, possibly because their heart attacks were twice as severe as those in mice who did not have the mutated gene.

A similar two-fold increase in heart failure was observed when mice with a mutated BRCA1 or BRAC2 gene were treated with doxorubicin, one of the most common for patients with . In addition to studies in mice, the authors also verified this observation in human tissues.

The researchers believe that the mutated BRCA1/2 prevents DNA repair in that is essential to recovery after a heart attack.

Their findings were published in the journals Nature Communications and .

"Our findings suggest that individuals who are at risk of breast cancer may also be at a previously unrecognized risk of heart disease," Dr. Verma said. "More importantly, we now understand that breast cancer and heart disease -- the two leading causes of death for Canadian women – have a common biological basis, a common soil."

Dr. Verma emphasized that these findings may have important implications for patients. Knowing that the BRCA1/2 gene is essential to may lead to future treatments for anyone with heart disease, a leading cause of death worldwide. Women who carry this mutated gene now know they may also be at a higher risk for developing heart disease in addition to the risk of developing cancer.

Dr. Christine Brezden-Masley, an oncologist at St. Michael's and a co-author of the paper, said that while physicians knew doxorubicin was associated with , the new research shows women with the mutated BRCA1/2 gene are particularly sensitive to its toxicity.

"What this means is that when a patient has the mutated gene, I now have to think about how much doxorubicin I'm going to give them or whether we should consider an alternate therapy," Dr. Brezden-Masley said.

Related Stories

Recommended for you

Maternal diet may program child for disease risk, but better nutrition later can change that

October 20, 2017
Research has shown that a mother's diet during pregnancy, particularly one that is high-fat, may program her baby for future risk of certain diseases such as diabetes. A new study from nutrition researchers at the University ...

New gene editing approach for alpha-1 antitrypsin deficiency shows promise

October 20, 2017
A new study by scientists at UMass Medical School shows that using a technique called "nuclease-free" gene editing to correct cells with the mutation that causes a rare liver disease leads to repopulation of the diseased ...

Researchers find evidence of DNA damage in veterans with Gulf War illness

October 19, 2017
Researchers say they have found the "first direct biological evidence" of damage in veterans with Gulf War illness to DNA within cellular structures that produce energy in the body.

Researchers drill down into gene behind frontotemporal lobar degeneration

October 19, 2017
Seven years ago, Penn Medicine researchers showed that mutations in the TMEM106B gene significantly increased a person's risk of frontotemporal lobar degeneration (FTLD), the second most common cause of dementia in those ...

Genetic variants associated with obsessive-compulsive disorder identified

October 18, 2017
(Medical Xpress)—An international team of researchers has found evidence of four genes that can be linked to obsessive-compulsive disorder (OCD). In their paper published in the journal Nature Communications, the group ...

New clues to treat Alagille syndrome from zebrafish

October 18, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies potential new therapeutic avenues for patients with Alagille syndrome. The discovery, published in Nature Communications, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.